TradingKey – Johnson & Johnson (JNJ) heads into Q3 with multiple positive catalysts. These include growth in the company’s pharmaceutical business, expansion in the MedTech business and the recently announced ICOTYDE data in psoriasis. The company closed at $261.44 on October 9, up 1.93% from the previous close. The primary catalyst is the expected third quarter earnings report to be released on October 13.
ICOTYDE Delivers Durable Two-Year Psoriasis Results
On October 9, J&J announced the two-year results of its Phase 3 ICONIC-LEAD study which showed durable responses through Week 112, for adults and adolescents with moderate-to-severe plaque psoriasis. At least 72% of patients treated with ICOTYDE (icotrokinra) achieved PASI 90, at…
